---
created_on: 2026-02-13T15:40
last_updated: 2026-02-13T15:50
---
# Clinical and Pathophysiological Foundations of Distal Renal Tubular Acidosis: A Comprehensive Expert Guide to ATP6V0A4-Mediated Pathogenesis

Distal renal tubular acidosis (dRTA), historically categorized as Type 1 RTA, represents a complex and multifaceted clinical challenge characterized by the kidney's inability to establish a physiological pH gradient in the distal segments of the nephron. While the clinical hallmarks—hyperchloremic metabolic acidosis, hypokalemia, and nephrocalcinosis—are well-defined, the underlying molecular pathology often involves highly specific genetic aberrations. Among these, mutations in the _ATP6V0A4_ gene are a primary cause of the autosomal recessive form of the disease. This report provides a high-level academic and clinical synthesis of the pathophysiology, genetic architecture, and systemic manifestations of _ATP6V0A4_-related dRTA, designed to serve as an exhaustive reference for the primary care physician.

## Molecular Biology of the Vacuolar H+-ATPase and the Role of ATP6V0A4

The maintenance of systemic acid-base homeostasis is a fundamental requirement for nearly all biological processes. The kidney plays a central role in this homeostasis through two primary mechanisms: the reabsorption of filtered bicarbonate in the proximal tubule and the secretion of fixed metabolic acids in the distal tubule. The latter process is primarily mediated by $\alpha$-intercalated cells located in the collecting duct. At the apical membrane of these cells, the vacuolar $H^+$-ATPase (V-ATPase) functions as an ATP-driven proton pump, actively extruding hydrogen ions ($H^+$) into the tubular lumen against a significant electrochemical gradient.

The V-ATPase is a multi-subunit enzyme complex composed of two main domains: the peripheral $V_1$ domain, which contains the catalytic sites for ATP hydrolysis, and the integral $V_0$ domain, which facilitates proton translocation across the lipid bilayer. The _ATP6V0A4_ gene, located on chromosome 7q33-34, encodes the a4 subunit of the $V_0$ domain. This specific subunit is of particular clinical interest because its expression is largely restricted to a few specialized tissues, most notably the kidney and the inner ear. In the renal collecting duct, the a4 subunit is essential for the proper assembly and targeting of the V-ATPase complex to the apical membrane of $\alpha$-intercalated cells. Consequently, mutations in _ATP6V0A4_ lead to a functional failure of these cells to acidify the urine, resulting in the systemic accumulation of metabolic acids and the clinical syndrome of dRTA.

### Structure and Function of the V-ATPase Complex

To understand the impact of _ATP6V0A4_ mutations, one must appreciate the stoichiometry of the V-ATPase pump. The complex consists of at least 13 different subunits. The $V_1$ domain (subunits A-H) and the $V_0$ domain (subunits a, d, c, c’, c’’, and e) must be precisely coordinated. The a4 subunit is one of several tissue-specific isoforms of the "a" subunit; others include a1 (ubiquitous), a2 (linked to cutis laxa), and a3 (linked to osteopetrosis). The replacement of generic subunits with tissue-restricted ones like a4 allow for specialized physiological functions, such as the extreme acidification required in the renal lumen and the maintenance of the delicate pH balance in the endolymph of the inner ear.

|**V-ATPase Domain**|**Component Subunits**|**Primary Function**|
|---|---|---|
|**$V_1$ (Peripheral)**|A, B, C, D, E, F, G, H|ATP hydrolysis; powers the rotational mechanism of the pump.|
|**$V_0$ (Integral)**|a, c, c', c'', d, e|Proton translocation; provides the channel for $H^+$ movement across the membrane.|
|**Specific Subunit a4**|Encoded by _ATP6V0A4_|Essential for targeting the pump to the apical membrane in the kidney and inner ear.|

## Pathophysiology of Distal Renal Tubular Acidosis

Distal renal tubular acidosis is fundamentally an acidification defect. Unlike proximal RTA (Type 2), where the primary issue is a "leak" of bicarbonate due to impaired reabsorption, dRTA involves a failure of the distal nephron to excrete the daily net acid load of approximately $1\text{ to }2\text{ mEq/kg/day}$ generated by protein metabolism.

### Mechanisms of Acidification Failure

In a healthy individual, the $\alpha$-intercalated cells utilize the apical V-ATPase pump to secrete $H^+$. This secretion is balanced by the basolateral $Cl^-$/$HCO_3^-$ exchanger (AE1, encoded by _SLC4A1_), which returns a "new" bicarbonate molecule to the systemic circulation for every proton excreted. When the a4 subunit is mutated, this apical proton extrusion is either severely diminished or entirely absent. This leads to several immediate physiological consequences:

1. **Inability to Lower Urinary pH:** Even in the presence of severe systemic metabolic acidosis, the urinary pH typically remains above 5.5, and often exceeds 6.0.
    
2. **Decreased Ammonium Excretion:** Protons secreted into the lumen are normally buffered by ammonia ($NH_3$) to form ammonium ($NH_4^+$), which is then trapped in the urine. In dRTA, the lack of luminal $H^+$ results in a failure of "ammonia trapping," significantly reducing the kidney's capacity for net acid excretion.
    
3. **Positive Urine Anion Gap:** The calculation of the urine anion gap ($UAG = [Na^+] + [K^+] - [Cl^-]$) is used to estimate urinary ammonium. In dRTA, the UAG is typically positive, indicating a deficit in $NH_4^+$ excretion.
    

### Comparison of Renal Tubular Acidosis Types

Primary care clinicians must distinguish dRTA from other RTA variants, as the management and long-term risks differ substantially.

|**Feature**|**Distal RTA (Type 1)**|**Proximal RTA (Type 2)**|**Hyperkalemic RTA (Type 4)**|
|---|---|---|---|
|**Primary Defect**|Impaired $H^+$ secretion in distal tubule|Impaired $HCO_3^-$ reabsorption in proximal tubule|Aldosterone deficiency or resistance|
|**Minimum Urine pH**|>5.5 (Always)|Variable (<5.5 if plasma $HCO_3^-$ is low)|<5.5|
|**Serum Potassium**|Low (Hypokalemia)|Low (Hypokalemia)|High (Hyperkalemia)|
|**Nephrocalcinosis**|Common/Severe|Rare|Rare|
|**Associated Genes**|_ATP6V0A4_, _ATP6V1B1_, _SLC4A1_|_SLC4A4_|Various (e.g., _SCNN1A_)|

## Genetic Architecture of ATP6V0A4 Mutations

The _ATP6V0A4_ mutation manifests as an autosomal recessive disorder, meaning affected individuals carry biallelic pathogenic variants. This genetic etiology explains the typical presentation in infancy or early childhood, although milder variants may go undetected until adulthood.

### Phenotypic Variability and Allelic Heterogeneity

The clinical severity of _ATP6V0A4_-related dRTA is highly variable. Some patients present in the neonatal period with life-threatening metabolic acidosis, failure to thrive, and severe dehydration. Others may exhibit an "incomplete" form of dRTA, where they maintain a normal systemic pH under basal conditions but demonstrate an inability to acidify urine under stress and are prone to recurrent nephrolithiasis.

Research has identified over 100 unique mutations in _ATP6V0A4_, ranging from point mutations (missense) to large deletions. Notably, patients with _ATP6V0A4_ mutations often present at a slightly older age than those with _ATP6V1B1_ mutations (median age 28 months vs. 14 months), and they may initially appear to have preserved hearing, whereas hearing loss in _ATP6V1B1_ is almost universally early-onset. However, long-term follow-up has revealed that sensorineural hearing loss (SNHL) is a frequent late manifestation of _ATP6V0A4_ defects, often developing in the second or third decade of life.

## Systemic Electrolyte Imbalances: The Challenge of Hypokalemia

Hypokalemia is a hallmark of distal RTA and a major cause of morbidity. The reduction in serum potassium is not a secondary effect of the acidosis but a direct consequence of the renal transport dysfunction.

### Pathophysiological Mechanisms of Potassium Wasting

In the distal tubule and collecting duct, sodium reabsorption creates a negative electrical potential in the lumen. Under normal conditions, this potential is partially neutralized by the secretion of hydrogen ions via the V-ATPase and potassium ions via the ROMK channel. In dRTA, the failure of V-ATPase-mediated $H^+$ secretion forces the kidney to increase potassium secretion to maintain electroneutrality.

Furthermore, the chronic metabolic acidosis leads to a state of mild volume depletion, which activates the renin-angiotensin-aldosterone system (RAAS). High levels of aldosterone stimulate sodium-potassium exchange in the principal cells of the collecting duct, further exacerbating urinary potassium losses. The clinical consequences of severe hypokalemia include profound muscle weakness, hyporeflexia, constipation, polyuria (due to nephrogenic diabetes insipidus), and in extreme cases, hypokalemic paralysis.

## Renal Mineralization: Nephrocalcinosis and Nephrolithiasis

The kidney in dRTA is under constant threat from the deposition of calcium phosphate. Nephrocalcinosis is seen in nearly all patients with _ATP6V0A4_ mutations and is a primary driver of long-term chronic kidney disease.

### The Synergistic Factors of Calcification

The high stone risk in dRTA is the result of a "perfect storm" of biochemical abnormalities:

1. **Hypercalciuria:** Chronic acidosis causes the release of calcium from the bone (skeletal buffering) and inhibits its reabsorption in the distal tubule.
    
2. **Hypocitraturia:** Citrate is the most important inhibitor of calcium crystal formation in the urine. Systemic acidosis leads to a massive increase in proximal tubular reabsorption and metabolism of citrate, resulting in extremely low urinary citrate levels.
    
3. **Alkaline Urine:** Calcium phosphate is significantly less soluble at higher pH. The persistently alkaline urine (pH > 6.0) in dRTA facilitates the rapid precipitation of apatite crystals.
    

Over time, these crystals deposit in the renal medulla (nephrocalcinosis) and form discrete stones in the collecting system (nephrolithiasis). While the renal function is often preserved for many years, the progression of calcification can eventually lead to scarring and a decline in the glomerular filtration rate (GFR).

|**Factor**|**Mechanism in dRTA**|**Impact on Stones**|
|---|---|---|
|**Urinary pH**|Inability to secrete $H^+$ results in pH > 5.5.|Promotes calcium phosphate precipitation.|
|**Urinary Citrate**|Acidosis-induced reabsorption in proximal tubule.|Loss of a key inhibitor of crystallization.|
|**Urinary Calcium**|Bone buffering and impaired renal reabsorption.|Increases supersaturation of calcium salts.|

## Skeletal Health: Osteopenia, Osteoporosis, and Rickets

The skeleton is far from a passive structure; it is an active metabolic participant in acid-base homeostasis. In the face of chronic metabolic acidosis, the bone functions as a massive chemical buffer, releasing alkaline salts to neutralize excess hydrogen ions.

### Skeletal Buffering and Bone Resorption

The dissolution of bone mineral in dRTA occurs through two distinct processes. Initially, there is a physicochemical exchange where protons enter the bone surface in exchange for sodium and potassium, followed by the direct dissolution of calcium carbonate and phosphate crystals.

However, the more damaging phase is cell-mediated. Chronic acidosis stimulates osteoclast activity and suppresses osteoblast function. This is driven by an increase in local prostaglandin production (specifically $PGE_2$), which upregulates the Receptor Activator of Nuclear Factor $\kappa$B Ligand (RANKL). RANKL is a critical signaling molecule that triggers the differentiation and activation of osteoclasts, leading to accelerated bone resorption.

### Clinical Presentation of Bone Disease

In pediatric patients, this process results in rickets, characterized by delayed mineralization of the growth plates, skeletal deformities, and significant growth retardation. In adults, the corresponding condition is osteomalacia, which often manifests as chronic bone pain and an increased risk of pathological fractures. If the acidosis is not rigorously corrected, patients will develop secondary osteopenia and osteoporosis, significantly increasing their lifelong fracture risk.

## Sensorineural Hearing Loss (SNHL) and ATP6V0A4

The association between dRTA and hearing loss is a critical aspect of the _ATP6V0A4_ phenotype. While _ATP6V1B1_ mutations typically cause severe, early-onset deafness, the hearing loss in _ATP6V0A4_ is often more insidious.

### The Stria Vascularis and Endocochlear Potential

The inner ear relies on the V-ATPase pump to maintain the unique ionic environment of the endolymph, which is high in potassium and low in sodium. This environment is necessary to generate the endocochlear potential, a voltage of $+80$ to $+100\text{ mV}$ that acts as the "battery" for the hair cells.

The a4 subunit is highly expressed in the interdental cells and the endolymphatic sac. Mutations in _ATP6V0A4_ disrupt the pH regulation of the endolymph, leading to a loss of the endocochlear potential and the progressive death of hair cells. Many patients also exhibit structural malformations of the inner ear, most notably the Enlarged Vestibular Aqueduct (EVA), which can be visualized on high-resolution CT imaging. Clinical monitoring requires annual audiometry, as the progression of SNHL is independent of the success of renal alkali therapy.

## Dental and Craniofacial Abnormalities

Recent research has expanded the phenotypic spectrum of dRTA to include significant dental anomalies. These findings are increasingly recognized as part of the syndromic presentation of primary dRTA.

### Amelogenesis Imperfecta and Hypodontia

The formation of tooth enamel (amelogenesis) is a highly pH-sensitive process. During the maturation stage of enamel development, the ameloblasts must extrude large amounts of acid as the hydroxyapatite crystals grow. Failure to regulate this local pH environment leads to enamel hypoplasia—a condition where the enamel is thin, soft, or entirely absent.

In patients with dRTA, dental findings frequently include:

- **Enamel Hypoplasia:** Pitted or discolored enamel that is prone to rapid decay.
    
- **Hypodontia:** The congenital absence of one or more teeth, often linked to the disruption of developmental signaling pathways during odontogenesis.
    
- **Delayed Secondary Eruption:** A failure of permanent teeth to erupt on time, sometimes associated with failure to shed primary teeth.
    

Primary care physicians should be aware that these dental findings may be the first clinical sign of an underlying systemic metabolic disorder, necessitating a referral for renal and metabolic evaluation.

## Clinical Management and the PCP’s Role in Surveillance

Management of _ATP6V0A4_-related dRTA is focused on the lifelong correction of the metabolic acidosis and the prevention of multi-organ complications. Because dRTA is a treatable condition, rigorous adherence to therapy can significantly alter the patient’s disease trajectory.

### Alkali Therapy: Strategies and Goals

The primary goal of treatment is to maintain a normal systemic pH and to normalize urinary mineral excretion. This is achieved through the oral administration of alkali salts.

|**Alkali Formulation**|**Benefits**|**Considerations**|
|---|---|---|
|**Potassium Citrate**|Corrects acidosis and hypokalemia; citrate inhibits stones.|First-line for most dRTA patients.|
|**Potassium Bicarbonate**|Directly provides buffer; excellent for acute hypokalemia.|May require frequent dosing.|
|**Sodium Bicarbonate**|Traditional choice; low cost.|Sodium load can increase urinary calcium excretion.|
|**ADV7103 (Sibnayal)**|Controlled-release formulation (Europe).|Allows for twice-daily dosing; improves adherence.|

**Dosing Targets for the PCP:**

- **Serum Bicarbonate:** $>22\text{ mmol/L}$ (Higher targets in children to promote growth).
    
- **Serum Potassium:** $\geq 3.5\text{ mEq/L}$.
    
- **Urinary Citrate:** $>320\text{ mg/day}$.
    
- **Urinary Calcium:** Maintain within age-appropriate reference ranges to prevent nephrocalcinosis.
    

### Long-term Monitoring and Precautions

Patients with _ATP6V0A4_ mutations require multidisciplinary care coordinated by the PCP, involving nephrology, audiology, and dentistry.

**Surveillance Schedule:**

- **Biochemical Labs:** Serum electrolytes, creatinine, and venous blood gas every 3–6 months.
    
- **Renal Ultrasound:** Annually to monitor for stones and the progression of nephrocalcinosis.
    
- **Audiometry:** Annually, especially in teenagers and young adults, to detect progressive SNHL.
    
- **Dental Exams:** Bi-annually to manage enamel defects and prevent rampant caries.
    

**Clinical Pearls for the PCP:**

- **Avoid Thiazides:** Thiazide diuretics are a common treatment for hypercalciuria but are **strictly contraindicated** in dRTA as they will dangerously worsen hypokalemia.
    
- **NSAID Avoidance:** Chronic use of NSAIDs should be discouraged to protect the already compromised kidneys from additional tubulointerstitial injury.
    
- **Pregnancy Management:** Women with dRTA require intensive monitoring during pregnancy, as they are at high risk for severe hypokalemia and worsening acidosis, especially if hyperemesis is present.
    

## Conclusion

Distal renal tubular acidosis caused by _ATP6V0A4_ mutations is a systemic disorder that extends far beyond the renal tubules. The molecular failure of the V-ATPase a4 subunit orchestrates a cascade of events—metabolic acidosis, potassium wasting, skeletal demineralization, and auditory decline—that requires a high index of suspicion and vigilant management. While the genetic defect itself cannot currently be corrected, the "crash course" in metabolic management presented here illustrates that with adequate alkali therapy and careful surveillance, patients can achieve normal growth, preserve renal function, and manage the extra-renal challenges of this rare condition. The primary care physician serves as the crucial navigator in this lifelong care journey, ensuring that metabolic stability remains the foundation for the patient’s overall health and well-being.

#### Works cited

1. Neonatal Onset Distal Renal Tubular Acidosis: Description of Two ..., accessed February 13, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC11534435/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11534435/)
    
2. (PDF) Novel ATP6V1B1 and ATP6V0A4 mutations in autosomal recessive distal renal tubular acidosis with new evidence for hearing loss - ResearchGate, accessed February 13, 2026, [https://www.researchgate.net/publication/11050348_Novel_ATP6V1B1_and_ATP6V0A4_mutations_in_autosomal_recessive_distal_renal_tubular_acidosis_with_new_evidence_for_hearing_loss](https://www.researchgate.net/publication/11050348_Novel_ATP6V1B1_and_ATP6V0A4_mutations_in_autosomal_recessive_distal_renal_tubular_acidosis_with_new_evidence_for_hearing_loss)
    
3. Renal Tubular Acidosis - StatPearls - NCBI Bookshelf, accessed February 13, 2026, [https://www.ncbi.nlm.nih.gov/sites/books/NBK519044/](https://www.ncbi.nlm.nih.gov/sites/books/NBK519044/)
    
4. ATP6V0A4 gene - MedlinePlus, accessed February 13, 2026, [https://medlineplus.gov/download/genetics/gene/atp6v0a4.pdf](https://medlineplus.gov/download/genetics/gene/atp6v0a4.pdf)
    
5. Atp6v0a4 knockout mouse is a model of distal renal tubular acidosis ..., accessed February 13, 2026, [https://www.pnas.org/doi/10.1073/pnas.1204257109](https://www.pnas.org/doi/10.1073/pnas.1204257109)
    
6. Renal tubular acidosis with deafness: MedlinePlus Genetics, accessed February 13, 2026, [https://medlineplus.gov/genetics/condition/renal-tubular-acidosis-with-deafness/](https://medlineplus.gov/genetics/condition/renal-tubular-acidosis-with-deafness/)
    
7. Mutations in ATP6V1B1 and ATP6V0A4 genes cause recessive distal renal tubular acidosis in Mexican families - PMC, accessed February 13, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC4867564/](https://pmc.ncbi.nlm.nih.gov/articles/PMC4867564/)
    
8. Type 1 distal Renal Tubular Acidosis (dRTA) - National Kidney Federation, accessed February 13, 2026, [https://www.kidney.org.uk/type-1-distal-renal-tubular-acidosis-drta](https://www.kidney.org.uk/type-1-distal-renal-tubular-acidosis-drta)
    
9. Renal Tubular Acidosis - A quick guide (2) - Society of Hospital Medicine, accessed February 13, 2026, [https://www.hospitalmedicine.org/globalassets/professional-development/clinical-quick-talks-pdfs/renal-tubular-acidosis-by-vikas-parekh.pdf](https://www.hospitalmedicine.org/globalassets/professional-development/clinical-quick-talks-pdfs/renal-tubular-acidosis-by-vikas-parekh.pdf)
    
10. Renal Tubular Acidosis - Genitourinary Disorders - MSD Manual Professional Edition, accessed February 13, 2026, [https://www.msdmanuals.com/professional/genitourinary-disorders/renal-transport-abnormalities/renal-tubular-acidosis](https://www.msdmanuals.com/professional/genitourinary-disorders/renal-transport-abnormalities/renal-tubular-acidosis)
    
11. Distal renal tubular acidosis: ERKNet/ESPN clinical practice points, accessed February 13, 2026, [https://www.erknet.org/fileadmin/Guidelines/Trepiccione_et_al.__2021__CPR_dRTA.pdf](https://www.erknet.org/fileadmin/Guidelines/Trepiccione_et_al.__2021__CPR_dRTA.pdf)
    
12. Renal Tubular Acidosis - StatPearls - NCBI Bookshelf, accessed February 13, 2026, [https://www.ncbi.nlm.nih.gov/books/NBK519044/](https://www.ncbi.nlm.nih.gov/books/NBK519044/)
    
13. Renal Tubular Acidosis: Core Curriculum 2025 - PubMed, accessed February 13, 2026, [https://pubmed.ncbi.nlm.nih.gov/39864011/](https://pubmed.ncbi.nlm.nih.gov/39864011/)
    
14. Distal renal tubular acidosis triggered by clozapine in a patient with a heterozygous ATP6V0A4 c.1029 + 5G > A variant: a case report and literature review - PMC, accessed February 13, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC12574289/](https://pmc.ncbi.nlm.nih.gov/articles/PMC12574289/)
    
15. A case report and literature review of primary distal renal tubular ..., accessed February 13, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC12696175/](https://pmc.ncbi.nlm.nih.gov/articles/PMC12696175/)
    
16. Hereditary Distal Renal Tubular Acidosis - GeneReviews® - NCBI ..., accessed February 13, 2026, [https://www.ncbi.nlm.nih.gov/books/NBK547595/](https://www.ncbi.nlm.nih.gov/books/NBK547595/)
    
17. Identification of novel pathogenic mutations in ATP6V0A4 associated with distal renal tubular acidosis and analysis of wild-type expression in glomerular disease - PMC, accessed February 13, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC12333040/](https://pmc.ncbi.nlm.nih.gov/articles/PMC12333040/)
    
18. A novel heterozygous mutation in the ATP6V0A4 gene encoding the V-ATPase a4 subunit in an adult patient with incomplete distal renal tubular acidosis - PMC, accessed February 13, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC4886904/](https://pmc.ncbi.nlm.nih.gov/articles/PMC4886904/)
    
19. Distal Renal Tubular Acidosis: Genetic and Clinical Spectrum - ERKNet, accessed February 13, 2026, [https://www.erknet.org/fileadmin/files/user_upload/Giglio_Distal_renal_tubular_acidosis.pdf](https://www.erknet.org/fileadmin/files/user_upload/Giglio_Distal_renal_tubular_acidosis.pdf)
    
20. Novel ATP6V1B1 and ATP6V0A4 mutations in autosomal recessive distal renal tubular acidosis with new evidence for hearing loss - PubMed, accessed February 13, 2026, [https://pubmed.ncbi.nlm.nih.gov/12414817/](https://pubmed.ncbi.nlm.nih.gov/12414817/)
    
21. Inner ear abnormalities in four patients with dRTA and SNHL: clinical and genetic heterogeneity - PubMed, accessed February 13, 2026, [https://pubmed.ncbi.nlm.nih.gov/19639346/](https://pubmed.ncbi.nlm.nih.gov/19639346/)
    
22. Hypokalemia Related to Distal Renal Tubular Acidosis as an Initial Presentation of Primary Sjogren's Syndrome, accessed February 13, 2026, [https://www.actamedindones.org/index.php/ijim/article/download/2220/pdf/11517](https://www.actamedindones.org/index.php/ijim/article/download/2220/pdf/11517)
    
23. A case report and literature review of primary distal renal tubular acidosis resulting from a mutation in ATP6V0A4 - Frontiers, accessed February 13, 2026, [https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2025.1685798/full](https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2025.1685798/full)
    
24. Distal Renal Tubular Acidosis, Hypokalemic Paralysis, Nephrocalcinosis, Primary Hypothyroidism, Growth Retardation, Osteomalacia and Osteoporosis Leading to Pathological Fracture: A Case Report - PMC, accessed February 13, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC3191715/](https://pmc.ncbi.nlm.nih.gov/articles/PMC3191715/)
    
25. Childhood nephrolithiasis and nephrocalcinosis caused by metabolic diseases and renal tubulopathy: A retrospective study from 2 tertiary centers - PMC, accessed February 13, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC9280569/](https://pmc.ncbi.nlm.nih.gov/articles/PMC9280569/)
    
26. Incomplete distal renal tubular acidosis and kidney stones - BORIS Portal, accessed February 13, 2026, [https://boris-portal.unibe.ch/bitstreams/6f63bf5c-ab24-4c38-9c06-1ecbc52061ad/download](https://boris-portal.unibe.ch/bitstreams/6f63bf5c-ab24-4c38-9c06-1ecbc52061ad/download)
    
27. Effects of acid on bone - PMC, accessed February 13, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC9133222/](https://pmc.ncbi.nlm.nih.gov/articles/PMC9133222/)
    
28. Hypocitraturia and Renal Calculi - StatPearls - NCBI Bookshelf, accessed February 13, 2026, [https://www.ncbi.nlm.nih.gov/books/NBK564392/](https://www.ncbi.nlm.nih.gov/books/NBK564392/)
    
29. Hypocitraturia: Pathophysiology and Medical Management - PMC, accessed February 13, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC2777061/](https://pmc.ncbi.nlm.nih.gov/articles/PMC2777061/)
    
30. Hypocitraturia and its role in renal stone disease, accessed February 13, 2026, [https://cdn-uat.mdedge.com/files/s3fs-public/issues/articles/media_5519ef2_ccjm55_3-0242.pdf](https://cdn-uat.mdedge.com/files/s3fs-public/issues/articles/media_5519ef2_ccjm55_3-0242.pdf)
    
31. What is the treatment approach for a patient with distal Renal Tubular Acidosis (RTA)?, accessed February 13, 2026, [https://www.droracle.ai/articles/797584/what-is-the-treatment-approach-for-a-patient-with](https://www.droracle.ai/articles/797584/what-is-the-treatment-approach-for-a-patient-with)
    
32. Mechanism of acid-induced bone resorption - PubMed - NIH, accessed February 13, 2026, [https://pubmed.ncbi.nlm.nih.gov/15199293/](https://pubmed.ncbi.nlm.nih.gov/15199293/)
    
33. Cellular mechanisms of bone resorption induced by metabolic acidosis - PubMed - NIH, accessed February 13, 2026, [https://pubmed.ncbi.nlm.nih.gov/14629607/](https://pubmed.ncbi.nlm.nih.gov/14629607/)
    
34. Clinical outcome of children with primary distal renal tubular acidosis - ResearchGate, accessed February 13, 2026, [https://www.researchgate.net/publication/51856364_Clinical_outcome_of_children_with_primary_distal_renal_tubular_acidosis?_tp=eyJjb250ZXh0Ijp7InBhZ2UiOiJzY2llbnRpZmljQ29udHJpYnV0aW9ucyIsInByZXZpb3VzUGFnZSI6bnVsbH19](https://www.researchgate.net/publication/51856364_Clinical_outcome_of_children_with_primary_distal_renal_tubular_acidosis?_tp=eyJjb250ZXh0Ijp7InBhZ2UiOiJzY2llbnRpZmljQ29udHJpYnV0aW9ucyIsInByZXZpb3VzUGFnZSI6bnVsbH19)
    
35. Oral Manifestations in a Child With Distal Renal Tubular Acidosis, and Refractory Rickets | Request PDF - ResearchGate, accessed February 13, 2026, [https://www.researchgate.net/publication/388082045_Oral_Manifestations_in_a_Child_With_Distal_Renal_Tubular_Acidosis_and_Refractory_Rickets](https://www.researchgate.net/publication/388082045_Oral_Manifestations_in_a_Child_With_Distal_Renal_Tubular_Acidosis_and_Refractory_Rickets)
    
36. Metabolic Acidosis Depletes Bone - Optimal DX FYI, accessed February 13, 2026, [https://www.optimaldx.com/research-blog/optimal-dx-fyi-metabolic-acidosis-depletes-bone](https://www.optimaldx.com/research-blog/optimal-dx-fyi-metabolic-acidosis-depletes-bone)
    
37. Renal Tubular Acidosis Manifesting as Severe Metabolic Bone Disease - PMC, accessed February 13, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC8320014/](https://pmc.ncbi.nlm.nih.gov/articles/PMC8320014/)
    
38. Mice deficient in H+-ATPase a4 subunit have severe hearing impairment associated with enlarged endolymphatic compartments within the inner ear, accessed February 13, 2026, [https://journals.biologists.com/dmm/article/6/2/434/20069/Mice-deficient-in-H-ATPase-a4-subunit-have-severe](https://journals.biologists.com/dmm/article/6/2/434/20069/Mice-deficient-in-H-ATPase-a4-subunit-have-severe)
    
39. Hearing Loss Related to Gene Mutations in Distal Renal Tubular Acidosis, accessed February 13, 2026, [https://fatihozaltin.com/uploads/file/65ea9c143c2fe4.61379676-1709874196.pdf](https://fatihozaltin.com/uploads/file/65ea9c143c2fe4.61379676-1709874196.pdf)
    
40. Stuck Below: Failure of Tooth Eruption and Hereditary Enamel Defects - PMC, accessed February 13, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC12375193/](https://pmc.ncbi.nlm.nih.gov/articles/PMC12375193/)
    
41. DISEASES - MMP20 - JensenLab, accessed February 13, 2026, [https://diseases.jensenlab.org/Entity?documents=10&type1=9606&id1=ENSP00000260228&type2=-26&id2=DOID:5608](https://diseases.jensenlab.org/Entity?documents=10&type1=9606&id1=ENSP00000260228&type2=-26&id2=DOID:5608)
    
42. Short stature (Concept Id: C0349588) - NCBI, accessed February 13, 2026, [https://www.ncbi.nlm.nih.gov/medgen/87607](https://www.ncbi.nlm.nih.gov/medgen/87607)
    
43. The First Report of a Missense Variant in RFX2 Causing Non-Syndromic Tooth Agenesis in a Consanguineous Pakistani Family - Frontiers, accessed February 13, 2026, [https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2021.782653/full](https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2021.782653/full)
    
44. Clinical Appearances of Hypomaturation AI in Patients with WDR72... - ResearchGate, accessed February 13, 2026, [https://www.researchgate.net/figure/Clinical-Appearances-of-Hypomaturation-AI-in-Patients-with-WDR72-Mutations-A-and-B-The_fig2_38032701](https://www.researchgate.net/figure/Clinical-Appearances-of-Hypomaturation-AI-in-Patients-with-WDR72-Mutations-A-and-B-The_fig2_38032701)
    
45. Renal Tubular Acidosis - Genitourinary Disorders - Merck Manual Professional Edition, accessed February 13, 2026, [https://www.merckmanuals.com/professional/genitourinary-disorders/renal-transport-abnormalities/renal-tubular-acidosis](https://www.merckmanuals.com/professional/genitourinary-disorders/renal-transport-abnormalities/renal-tubular-acidosis)
    
46. Invitae Nephrolithiasis Panel - Labcorp, accessed February 13, 2026, [https://www.labcorp.com/content/dam/genetics/CD/Invitae%20-%20Invitae%20Nephrolithiasis%20Panel%20-%20Clinical%20Description.pdf](https://www.labcorp.com/content/dam/genetics/CD/Invitae%20-%20Invitae%20Nephrolithiasis%20Panel%20-%20Clinical%20Description.pdf)
    

**
